Home Ianalumab in Sjögren’s syndrome: what can we learn from lupus trials? – Authors’ reply.
|

Ianalumab in Sjögren’s syndrome: what can we learn from lupus trials? – Authors’ reply.

Print
Share

Also of interest

New mechanism of cortisone action deciphered

Sjögren-Tag 2024 am 6. April bei der Deutschen Rheuma-Liga Berlin

Sign up for the
DRFZ NewsFlash